Technology
For the approximately 15 million people examined for lung cancer each year, there is an abundant and compelling need for cost effective, non-invasive technology that may be used in conjunction with CT imaging to confirm pre-surgical staging and diagnosis.
According to Mayo Clinic estimates, up to 94% of CT scans for high risk patients show abnormalities that are not cancer. Many of these patients face unnecessary surgical biopsies that result in additional health care expenses, extensive recovery time, anguish and even death. Surgical biopsies by thoracotomy typically cost $70,000, require 9 weeks recovery, and face a mortality rate of nearly 5%.
Freshmedx’s patented computerized bioconductance scanning technology significantly reduces the number of patients referred for biopsy unnecessarily by recording high precision transthoracic bioelectrical conductance measurements that produce profiles to match benign and malignant chest conditions.
Clinical Results
Freshmedx's improvement to current lung cancer staging and diagnosis can save thousands of lives and billions of dollars in the U.S. health care system each year.
Four clinical trials completed in the US. Most recently, the second highest ranked medical research institution conducted a Freshmed-sponsored trial that demonstrated that Freshmed’s technology discriminates between cancerous and benign lung masses achieving accuracy levels above 90%. Freshmed’s improvement to current lung cancer staging and diagnosis can save thousands of lives and billions of dollars in the US healthcare system each year.
The Impact of Freshmedx AccuracyFreshmedx’s improvement to current lung cancer staging and diagnosis can save thousands of lives and billions of dollars in health care costs each year. Chart Source: The New England Journal of Medicine "reducing the number of futile thoracotomies" 07.02 |
CT Scan |
Freshmedx |
||
| % of Unnecessary Surgical Biopsies | 71% | < 10% | ||
| US Surgical Biopsies with Benign Findings | 528,980* | < 74,400 | ||
| Surgical Cost to U.S. Health care | $8.1B* | < $1.14B |
